Technological changes can balance or recoup the investments made to create them. Amid pricing and market pressures, these opportunities and increases in resource efficiency can help enhance the patient experience and improve R&D potential and returns.
RELATED ARTICLES
Moving Toward a Value-Driven Health Care System
To advance a value-driven care system, we need better information, a focus on outcomes that matter to patients and flexible new approaches to paying for medicines.
Improving Health Care Quality While Reducing Costs
The latest immunosuppressant therapies are transforming the lives of patients in ways beyond physical success. Innovations in treatment not only help extend life, they can also reduce health care costs to give back confidence and hope to patients for the future.
Innovative Medicines Deserve an Innovative Payment System
Over the past several years, we've witnessed an unprecedented pace of innovation which has ushered in a new era of medicine.
Policy Solutions to Push Progress Forward
We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we must not take this progress for granted.
Our Commitment
We are America's Biopharmaceutical Companies, driven to discover the next lifesaving breakthrough and dedicated to ending the burdens of disease. And with new, innovative medicines on the horizon, we're closer than ever to reaching our goal.
A Critical Quest: Working Toward Better Treatments for Brain Cancer
Glioblastoma is the most aggressive form of brain cancer, and one that impacts more than 12,000 Americans each year.
Researcher Profile: Dan Skovronsky
A neuroscientist and neuropathologist by training, Dan is responsible for development across all of Lilly's products - from clinical trials through approvals - specifically working within the areas of oncology, diabetes, Alzheimer's disease, immunology and pain management.
Lifecycle from Brand to Generic
Where do generic drugs come from? Medicines have a long lifecycle from research to brand name drug to generic form. Over time, innovation leads to increased competition on price and clinical effects.
Research Doesn’t End On A Medicine’s Approval
Research on a medicine doesn't end on the initial approval by the FDA. Eli Lilly and Company's chief medical officer shares why ongoing research helps us better understand a medicine's full value.
Can We Afford the New Era of Medicine?
Innovative treatments require innovative partnerships. America's Biopharmaceutical Companies and insurers are partnering to get the right medicine in the hands of patients who need them.
The American Innovation Engine: Keeping the United States Competitive for Biopharmaceutical Investors
Investment is a key driver of innovation across all industries. However, investment is especially important to the research-intensive biopharmaceutical industry.
A New Age of Viral Disease Treatment: The Cure Developed by Biopharmaceutical Companies that Saved a Mother of Six
Hepatitis C kills more Americans than any other infectious disease. Carleen was one of those affected. She had five children and was pregnant with her sixth when she was diagnosed with the disease.
